肿瘤细胞治疗研究
英文原题：Successful Cord Blood Transplantation for Myeloid/Natural Killer Precursor Acute Leukemia: A Case Report and Literature Review.
一名21岁男性被诊断为髓系/自然杀伤前体白血病（MNKPL），骨髓浸润原始细胞免疫表型为cyCD3+、CD7+、CD33+、CD34 dim、CD56 +/-、HLA-DR+、cyMPO+和TdT-。
一名21岁男性被诊断为髓系/自然杀伤前体白血病（MNKPL），骨髓浸润原始细胞免疫表型为cyCD3+、CD7+、CD33+、CD34 dim、CD56+/-、HLA-DR+、cyMPO+和TdT-。尽管超分割环磷酰胺、多柔比星、长春新碱、地塞米松治疗未成功，但使用伊达比星和阿糖胞苷诱导治疗获得完全缓解（CR）。患者随后接受了清髓性预处理方案的脐血移植，获得了持久CR和完全供者嵌合。自移植以来，他已保持良好健康状态，无复发超过九个月。及时使用可用供者来源进行异基因造血干细胞移植可能是MNKPL的一种有前景的治疗策略。
A 21-year-old man was diagnosed with myeloid/natural killer precursor leukemia (MNKPL) with bone marrow infiltration of blasts of cyCD3 + , CD7 + , CD33 + , CD34 dim , CD56 +/- , HLA-DR + , cyMPO + , and TdT - immunophenotypes. Although hyper-hyperfractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone therapy was unsuccessful, induction treatment with idarubicin and cytarabine resulted in complete remission (CR). The patient subsequently underwent cord blood transplantation with a myeloablative conditioning regimen, which resulted in durable CR and complete donor chimerism. He had been in good health without relapse for over nine months since transplantation. Timely allogeneic hematopoietic stem cell transplantation using an available donor source may be a promising treatment strategy for MNKPL.
MEMBER ACCOUNT
登录成功会直接打开下一页。
